KLRS · Kalaris Therapeutics Inc
United States · RS rating 7 · As of 2026-11-03
| Price | 2.05 USD |
|---|---|
| 1-day change | +2.5% |
| RS rating (overall / 1M / 3M / 12M) | 7 / 14 / 8 / 17 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 19 / 2 / 31 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -4.3% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +81.3% |
| Market cap (USD) | $139.9M |